Volume 4 Supplement 2

Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access

Molecular genetic study of female cancers in Novosibirsk, Russia

BMC Proceedings20104(Suppl 2):O21

DOI: 10.1186/1753-6561-4-S2-O21

Published: 24 September 2010

Female cancers such as breast (BC), endometrial (EC) and ovarian (OC) cancers show a growing incidence rate all over the world including Russia. In Novosibirsk city the incidence of BC, EC and OC is approximately 80, 25 и 12 per 100 000 in female population, respectively. In Novosibirsk population EC is most commonly found between the ages of 55 and 60 years, OC – between 45-60 and 55-60 years, BC – between 45-60 years. The age maximum for uterus myoma and endometrial hyperplasia was 45-50 and 40-45 years respectively. Thus, the peak incidence occurs in the post-menopausal age group for women with cancer and pre-menopausal age group for women with benign tumors. It is generally accepted that estrogens contribute greatly to the growth and development of these tumors. We estimated a frequency of allelic variants of estrogen-metabolizing enzymes CYP1A1, CYP1A2, CYP19 (aromatase) and II-phase enzyme SULT1A1 (Sulfotransferase) genes in the female Caucasian population in Novosibirsk region of Russia and their association with the elevated risk of female cancers. We have shown that for BC significant differences in the allele distributions for CYP1A1 M1 polymorphism between patients (n = 286) and controls (n = 274) were found (OR = 2.05, p = 0.000004). There is a deficiency of a mutant allele A of CYP1A2*1F in BC patients (OR = 0.72, p = 0.0023) as well as genotypes A/A homozygote’s (OR = 0.048, p = 0.0042) which exhibited a reduction of BC risk. Women with mutant allele A (OR = 2,03, p = 0.0003) and genotypes SULT1A1 AG heterozygote’s (OR = 2,22, p = 0.000005) and homozygote’s A/A (OR = 4,25, p = 0.000004) of SULT1A1 gene exhibited an increase of BC risk. We examined how genotype was related to the risk of developing an ER-positive (ER+) and PR-positive (PR+) BC tumor. We have shown the risk of an ER+ breast tumor seemed smaller for individuals with the CYP1A1, CYP19 and SULT1A1 variant allele and genotypes. The remarkable differences in the allele and genotype distributions for CYP1A2*1F polymorphism in patients with OC (n = 125) were found (OR = 0.26, p = 0.0000005). The frequency of a mutant CYP19 heterozygote genotype C/T was higher in patients with OC and EC (n = 168) compared to healthy women (OR = 3.87, p = 0.001 and OR = 3.73, p = 0.0004, respectively). The detection of estrogen-metabolizing enzymes in tumor is also important tool for the treatment and prognosis of cancer. We determined the expression of ERα, ERβ, CYP19, SULT1E1 and STS genes in studied tumors and revealed several tumor phenotypes. We have shown the ER+, CYP19+ phenotype in both BC and EC (60 and 80% cases respectively), whereas ER-, CYP19- (20% cases) phenotypes was found in BC only. We also have shown ER-, CYP19+ phenotype in 20% cases of BC and EC that could be important for the personalized treatment with aromatase inhibitors. The expression of STS was increased in 80% of EC tumors. Thus, studied genes could be appropriate candidates for our understanding their contribution to endocrine disorders and environmentally determined diseases susceptibility. Various patterns of ER α, β, CYP19, STS gene expression are promising tool for the personal treatment of female cancers in additional to HER2/neu and other target genes.



This work was supported by Federal program “Research and scientific-pedagogical personnel of innovation Russia in 2009-2013” code NC-543P,# P600.

Authors’ Affiliations

Novosibirsk State University, Novosibirsk, Russia and Institute of Molecular Biology and Biophysics


© Gulyaeva; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.